Related by context. All words. (Click for frequent words.) 72 NGX# 71 Phase 2a 70 Phase 2a clinical 70 cannabinor 70 phase IIa clinical 70 tezampanel 70 Phase IIa trial 69 Mipomersen 69 R#/MEM # 69 Phase 2a trial 69 INCB# [001] 69 Phase 2b study 68 GALNS 68 PEG PAL 68 phase IIb clinical 68 Pimavanserin 68 Phase IIa 68 PSN# [002] 68 Phase 1b trial 68 Phase IIb trials 68 Phase Ib 68 alvespimycin 67 KRN# 67 Phase IIa trials 67 diabetic neuropathic pain 67 PDE4 inhibitor 67 forodesine 67 Synavive 67 bicifadine 67 Lu AA# 67 PS# [001] 67 LY# [003] 67 metaglidasen 67 phase IIa 66 Phase 2b 66 selective androgen receptor modulator 66 elotuzumab 66 Archexin 66 Phase 2b trial 66 Phase IIb trial 66 Bicifadine 66 JAK inhibitor 66 CORT # 66 Phase 2b clinical 66 TriRima 66 Dapagliflozin 66 Tyrima 66 Phase IIB 66 vilazodone 66 Phase IIb clinical 66 Phase IIa clinical 66 Phase 1b 66 GLYX 66 CRx 66 PEG Interferon lambda 66 HGS# 65 Phase Ib study 65 MAP# 65 PEG SN# 65 Plicera 65 APD# 65 Serdaxin 65 phase IIb trial 65 BAY #-# 65 Corlux 65 Phase IIa clinical trials 65 ISIS # 65 Sym# 65 BCX# 65 Ophena TM 65 PXD# 65 Memryte 65 BEMA Buprenorphine 65 DDP# 65 RSD# oral 65 otelixizumab 65 Phase 1a clinical 65 phase IIb 64 Phase IIb 64 Tasimelteon 64 TELINTRA 64 VA# [002] 64 pramlintide 64 MEK inhibitor 64 OMNARIS HFA 64 SAR# [004] 64 MDV# 64 Clonicel 64 axitinib 64 Phenoptin 64 Phase Ib clinical 64 pertuzumab 64 elagolix 64 ganetespib 64 Panzem R 64 Traficet EN 64 HGS ETR1 64 RDEA# 64 ICA # 64 Vilazodone 64 pseudobulbar affect PBA 64 placebo controlled clinical 64 aplindore 64 tasimelteon 64 TBC# 64 tezampanel NGX# 64 Phase III clinical trials 64 RGB # 64 phase 2a 64 ProSavin 64 Triolex 64 incyclinide 64 Phase III clinical 64 orally bioavailable 63 teduglutide 63 dyskinesia PD LID 63 LY# [002] 63 multiple ascending dose 63 deforolimus 63 Ostarine 63 dirucotide 63 sapacitabine 63 PRT# 63 lomitapide 63 enzastaurin 63 Oral NKTR 63 AEG# 63 Cannabinor 63 tiapamil 63 Panzem R NCD 63 ELND# 63 lintuzumab SGN 63 adipiplon 63 Bezielle 63 GLPG# 63 oral prodrug 63 CR# vcMMAE 63 Phase 1b clinical 63 IPL# 63 MAGE A3 ASCI 63 class mGluR5 inhibitor 63 Phase 2a clinical trials 63 investigational humanized monoclonal antibody 63 Golimumab 63 Azixa 63 RG# [001] 63 Nanobody 63 muraglitazar 63 Abiraterone acetate 63 Elagolix 63 registrational 63 ALN VSP 63 phase Ib 63 placebo controlled Phase 63 ELADUR 63 OXi# 63 alvimopan 63 CCR9 antagonist 63 HCV protease inhibitor 63 orally administered inhibitor 63 eltrombopag 62 XmAb# 62 ADX# 62 Androxal TM 62 confirmatory Phase III 62 pivotal Phase III 62 methylnaltrexone 62 EOquin 62 confirmatory Phase 3 62 TMC# [002] 62 mipomersen 62 torezolid phosphate 62 TG# [003] 62 investigational compound 62 lintuzumab 62 MGCD# [001] 62 NUVIGIL 62 ELACYT 62 Phase III trials 62 Nasulin 62 IMC A# 62 Milnacipran 62 SNT MC# 62 vidofludimus 62 Phase Ia 62 CCX# 62 GSK# [002] 62 lesinurad 62 Safinamide 62 oral ridaforolimus 62 QVA# 62 dexanabinol 62 EndoTAG TM -1 62 JAK2 inhibitor 62 pomalidomide 62 evaluating tivozanib 62 glufosfamide 62 Imprime PGG 62 PNP inhibitor 62 Androxal ® 62 Sapacitabine 62 midstage clinical 62 investigational drug 62 Chemophase 62 Diamyd ® 62 Zenvia ™ 62 MLN# 62 octreotide implant 62 investigational oral 62 AZD# 62 nalbuphine ER 62 VEGF Trap 62 Ocrelizumab 62 compound INCB# 62 FOLOTYN ® 62 Phase #b/#a 62 NP2 Enkephalin 62 LymphoStat B 62 REG1 62 Atiprimod 62 PLK1 SNALP 62 Lixivaptan 62 Phase #b/#a trial 62 custirsen 62 IDX# 62 Tesetaxel 62 dosing cohort 62 Relovair 62 ponatinib 62 IIa trial 62 Fibrillex TM 62 Laquinimod 62 CA4P 62 Empatic 62 Genz # 62 NVA# 62 alagebrium 62 huC# DM4 62 Hsp# inhibitor 62 ZOLINZA 62 aflibercept 62 ocrelizumab 62 registrational trial 62 ApoB SNALP 62 TOCOSOL Paclitaxel 62 BNC# 62 mGluR2 NAM 62 AEGR 62 avanafil 62 EP #R 62 PD LID 62 AZILECT R 62 pradefovir 62 TRIOLEX 62 Trofex 62 Guanilib 62 dimebon 62 alemtuzumab Campath 61 INCB# [002] 61 R#/MEM 61 CORLUX 61 Urocortin 2 61 GAMMAGARD 61 midstage studies 61 CEQ# 61 riociguat 61 Troxatyl 61 HCD# [002] 61 INCB# [003] 61 Phase IIb clinical trials 61 HGS ETR2 61 Gabapentin GR 61 TACI Ig 61 Aurexis 61 tanespimycin 61 Serdaxin ® 61 Apoptone 61 mapatumumab 61 AP# [003] 61 Dextofisopam 61 intranasal formulation 61 angiogenesis inhibitor 61 PRTX 61 PHX# 61 iniparib 61 investigational pan BCR 61 Tolvaptan 61 Symadex 61 virus HCV protease inhibitor 61 visilizumab 61 IMC #B 61 Phase IIIb clinical 61 davalintide 61 AVE# 61 selective modulator 61 Microplasmin 61 preclinical 61 LAF# 61 peripherally acting 61 dexpramipexole 61 PSMA ADC 61 6R BH4 61 obatoclax 61 HuMax EGFr 61 YONDELIS 61 initiate Phase 1b 61 HuMax CD# 61 ENMD # 61 SILENOR TM 61 dextofisopam 61 ulimorelin 61 lumiliximab 61 cangrelor 61 ALKS 61 SARMs 61 GSK# [001] 61 urocortin 2 61 phase IIb study 61 Aflibercept 61 MYDICAR 61 midstage clinical trial 61 CB2 selective receptor agonist 61 pivotal bioequivalence 61 trial evaluating PRX# 61 rNAPc2 61 ruxolitinib 61 glucokinase activator 61 teplizumab 61 ZYBRESTAT 61 pivotal Phase 61 ularitide 61 Allovectin 7 R 61 ARRY 61 ALN PCS 61 TLK# 61 SLx 61 dacetuzumab 61 IMA# 61 synthetic retinoid 61 teriflunomide 61 daclizumab 61 ostarine 61 Fx #A 61 Aurora kinase inhibitor 61 REMOXY ® 61 trodusquemine 61 pharmacodynamic effects 61 generation purine nucleoside 61 pimavanserin 61 darapladib 61 mertansine 61 AGILECT R 61 omega interferon 61 CRLX# 61 linaclotide 61 Phase 2b clinical trials 61 refractory gout 61 eniluracil 61 NKTR 61 cediranib 61 CXB# 61 Stedivaze 61 SILENOR 61 vascular disrupting agent 60 Telaprevir 60 DPP4 inhibitor 60 talactoferrin 60 multitargeted 60 ALGRX 60 dextromethorphan quinidine 60 opioid induced bowel dysfunction 60 JAK1 60 metreleptin 60 oral rivaroxaban 60 CK # novel 60 BZL# 60 Phase III 60 dose escalation Phase 60 alogliptin 60 ANAVEX #-# [003] 60 oxymorphone ER 60 NLX P# 60 sodium glucose cotransporter 60 disease modifying 60 blinded randomized placebo controlled 60 NNR Therapeutics 60 IAP inhibitors 60 Arimoclomol 60 Phase Ib clinical trials 60 HuLuc# 60 XL# XL# XL# XL# 60 generation antisense 60 Phase #b/#a clinical 60 Desmoteplase 60 Optiquel ™ 60 omecamtiv mecarbil 60 Syncria 60 Romidepsin 60 INS# [001] 60 zileuton 60 Ceflatonin 60 bifeprunox 60 Amigal 60 RSD# 60 MGd 60 ALN TTR# 60 radiation sensitizer 60 Quinamed 60 oxypurinol 60 CK # 60 oral dosing 60 sorafenib Nexavar 60 Viprinex TM 60 Nuvion 60 THR beta agonist 60 Omnitarg 60 CDP# 60 Phase 1a 60 atacicept 60 Rasagiline 60 generation URAT1 inhibitor 60 Factor VIIa 60 bardoxolone methyl 60 BRAF inhibitor 60 brivaracetam 60 tolvaptan 60 Carfilzomib 60 Cetrorelix 60 odanacatib 60 Tanespimycin 60 lixivaptan 60 epothilone 60 LymphoStat B TM 60 Menerba 60 SinuNase 60 CYCLOSET 60 Phase Ib II 60 squalamine 60 JANUVIA 60 Hsp# Inhibitor 60 Phase 2a Clinical Trial 60 Azedra 60 Miraxion 60 BLA filing 60 vosaroxin 60 Asentar 60 clinical pharmacology studies 60 safinamide 60 Tezampanel 60 PDE# inhibitors 60 LEVADEX 60 inhaled formulation 60 ATL# [001] 60 MEND CABG II 60 Zenvia Phase III 60 Zenvia TM 60 almorexant 60 apremilast 60 insulin sensitizers 60 OncoGel 60 FOLFOX6 chemotherapy regimen 60 metastatic hormone refractory 60 Alzhemed TM 60 Sulonex 60 liprotamase 60 AeroLEF TM 60 Azedra TM 60 SUCCEED trial 60 preclinical studies 60 rufinamide 60 CoFactor 60 atrasentan 60 Androxal 60 Zingo TM 60 neurogenic orthostatic hypotension 60 fenofibric acid 60 IL# PE#QQR 60 ONCONASE R 60 orally administered 60 nucleotide analog 60 Sanctura XR 60 Technosphere Insulin 60 ozarelix 60 oral salmon calcitonin 60 PrevOnco 60 neratinib 60 TKM ApoB 60 Ereska 60 tarenflurbil 60 denufosol 60 solanezumab 60 sitaxsentan 60 darusentan 60 systemically administered 60 Omacetaxine 60 Nexavar ® 59 davunetide intranasal AL 59 regorafenib 59 MERLIN TIMI 59 oral formulation 59 Dasatinib 59 SCH # 59 bosutinib 59 Diabetic Macular Edema 59 docetaxel Taxotere R 59 E2F Decoy 59 ThGRF 59 investigational hepatitis C 59 Ramoplanin 59 CD# antibody [001] 59 Zerenex 59 receptor tyrosine kinase inhibitor 59 DCCR 59 TRO# 59 mGluR2 positive 59 oral methylnaltrexone 59 aripiprazole Abilify 59 Naproxcinod 59 desvenlafaxine 59 Posiphen 59 Personalized Immunotherapy 59 JAK3 inhibitor 59 APEX PD 59 XL# [003] 59 novel VDA molecule 59 administered subcutaneously 59 tafamidis 59 Pivotal Phase 59 GRN# 59 prGCD 59 TRV# [001] 59 Pivotal Trial 59 PI3K/Akt pathway inhibitor 59 Cinquil 59 Oxypurinol 59 ruboxistaurin 59 metastatic sarcomas 59 midstage trials 59 SRT# [003] 59 ospemifene 59 milnacipran 59 eprotirome 59 Exelixis compounds 59 severe hypercholesterolemia 59 CIMZIA TM 59 liposomal formulation 59 MBP# [001] 59 nitazoxanide 59 Sudhir Agrawal D.Phil 59 CTAP# Capsules 59 Pivotal Phase III 59 OHR/AVR# 59 arzoxifene 59 Vicriviroc 59 DermaVir Patch 59 telcagepant 59 Cloretazine ® 59 acyclovir Lauriad R 59 Anavex #-# 59 basal insulin analogue 59 MEK inhibitor RDEA# 59 Panzem 59 XL# XL# XL# 59 ixabepilone 59 velafermin 59 DR Cysteamine 59 drug pipeline TAFA# 59 Zybrestat 59 relapsed multiple myeloma 59 leading oral taxane 59 uric acid lowering 59 Iloperidone 59 Aclidinium 59 talabostat 59 mGluR5 NAM 59 J. Donald deBethizy 59 relapsing remitting multiple sclerosis 59 LibiGel ® 59 albiglutide 59 Hsp# inhibitors 59 sorafenib tablets 59 humanized anti 59 betrixaban 59 baminercept 59 lurasidone 59 multicenter Phase II 59 Neurodex 59 IND submission 59 phase III isavuconazole 59 tubulin inhibitor 59 preclinical efficacy 59 Lisofylline LSF 59 iloperidone 59 Xanafide 59 CYT# potent vascular disrupting 59 bafetinib 59 BYDUREON 59 preclinical pharmacokinetic 59 rALLy clinical trial 59 TOCOSOL Camptothecin 59 dalbavancin 59 schizophrenia CIAS 59 DEB# 59 norepinephrine reuptake inhibitor 59 urate lowering 59 lupus nephritis 59 EFAPROXYN 59 anti amnesic 59 SPP# [001] 59 Firazyr 59 Randomized Phase 59 Intervention Effectiveness 59 Proellex TM 59 QNEXA 59 URG# 59 RLY# 59 MYDICAR ® 59 HCV protease inhibitors 59 sunitinib malate 59 CINTREDEKIN BESUDOTOX 59 HepeX B 59 belinostat 59 cetrorelix 59 fosbretabulin 59 PEGylated Fab fragment 59 initiate Phase 2b 59 NXL# 59 eosinophilic asthma 59 Darusentan 59 investigational monoclonal antibody 59 next generation URAT1 59 CG# [003] 59 allosteric modulator PAM 59 PDX pralatrexate 59 Elocalcitol 59 generation PNP inhibitor 59 AQ4N 59 delta opioid receptor 59 USL# 59 Dr. Fahar Merchant 59 Zoraxel 59 nonclinical studies 59 generation proteasome inhibitor 59 CBLC# 59 ibudilast 59 Exenatide LAR 59 Lupuzor 59 ThermoDox R 59 Virulizin ® 59 exenatide LAR 59 Avanafil 59 Cloretazine R VNP#M 59 multi kinase inhibitor 59 nicotinic alpha 7 59 Daclizumab 59 ZYBRESTAT fosbretabulin 59 NV1FGF 59 Ron Bentsur 59 hyperphenylalaninemia HPA due 59 HER2 positive metastatic breast 59 relapsed refractory multiple myeloma 59 Reverset 59 EXPAREL TM 59 iSONEP 59 Alocrest 59 Valdoxan 59 EVIZON 59 Viprinex 59 trastuzumab DM1 T DM1 59 QuatRx 59 Zalbin 59 OMP #R# 59 EOquin TM 59 targeted radiotherapeutic 59 Phase IIb Trial 59 Spiegelmer ® 59 ACTEMRA TM 58 Locteron 58 CD NP 58 Zolinza 58 APF# 58 Phase 2b Clinical Trial 58 GGF2 58 hypoxia activated prodrug 58 droxidopa 58 FTY# fingolimod 58 bevirimat 58 JAK inhibitors 58 severe gastroparesis 58 IRX 2 58 AzaSite Plus 58 Capesaris 58 desvenlafaxine succinate 58 dacetuzumab SGN 58 perampanel 58 MEK inhibitors 58 Cethromycin 58 Acetavance 58 ACAPODENE 58 CIMZIA TM certolizumab pegol 58 randomized Phase IIb 58 REOLYSIN ® 58 budesonide foam 58 voreloxin 58 motesanib 58 CIMZIA ™ 58 Perifosine 58 diarrhea predominant irritable 58 GED aPC 58 PROMACTA 58 midstage clinical trials 58 ENDEAVOR IV 58 Phase #/#a trial 58 Major Depressive Disorder MDD 58 Cleviprex TM clevidipine 58 Ophena 58 subcutaneously administered 58 Silodosin 58 M6G 58 Unit Dose Budesonide 58 Annamycin 58 hepatitis C protease inhibitor 58 Linaclotide 58 Itopride 58 ITMN 58 PREOS 58 dose cohort 58 CB2 selective 58 Phase 1b clinical trials 58 Actilon 58 gamma secretase inhibitor 58 Dyloject TM 58 including eniluracil ADH 58 docetaxel chemotherapy 58 Promacta 58 carcinoid syndrome 58 CUDC 58 Voreloxin 58 PSN# [001] 58 ILUVIEN ® 58 fostamatinib 58 Ridaforolimus 58 Phase III Clinical Trial 58 seliciclib CYC# 58 Talabostat 58 Serada 58 serotonin norepinephrine reuptake inhibitor 58 Dimebon 58 ORENCIA R 58 vicriviroc 58 OvaRex ® MAb 58 Chrysalin 58 dose cohorts 58 bortezomib Velcade 58 ARIKACE ™ 58 AAG geldanamycin analog 58 Ozarelix 58 5 HT6 receptor 58 ORMD 58 nab paclitaxel 58 MAXY alpha 58 indiplon capsules 58 CCX# B 58 PA# [002] 58 XL# anticancer compounds 58 JZP 58 RhuDex 58 partial agonist 58 proteasome inhibitor 58 rasagiline tablets 58 APTIVUS r 58 SYN# 58 Ambrisentan 58 rindopepimut 58 KNS # 58 dirucotide MBP# 58 GPR# agonist 58 ADL# 58 romazarit 58 LEP ETU 58 APPRAISE 58 II Clinical Trial 58 entinostat 58 dose escalation phase 58 cariprazine 58 LCP AtorFen 58 tesmilifene 58 Genasense ® oblimersen 58 OMP #M# 58 CRD5 58 HCV polymerase inhibitors 58 CINOD 58 BRIM2 58 Civacir 58 NU# [001] 58 dimebon latrepirdine 58 canagliflozin 58 Contrave 58 HZT 58 PANVAC VF 58 reslizumab 58 Amrubicin 58 BEMA TM Fentanyl 58 octreotide acetate 58 sodium Injection 58 dosing cohorts 58 candidate XP# 58 integrase inhibitor 58 T DM1 58 Gaboxadol 58 receptor agonist 58 insulin degludec 58 Spiro Rombotis President 58 Shigamabs ® 58 antithrombotic 58 Pazopanib 58 Indibulin 58 Cloretazine 58 de novo kidney transplant 58 Marqibo 58 trospium 58 Atu# 58 FM VP4 58 Onalta ™ 58 FROVA 58 DU #b 58 Adentri 58 Revlimid lenalidomide 58 gaboxadol 58 epothilones 58 VAPRISOL 58 MAXY G# 58 LymphoStat B belimumab 58 tolevamer 58 multicenter Phase 58 aldehyde dehydrogenase ALDH2 deficiency 58 placebo controlled clinical trials 58 aliskiren 58 Jevtana 58 Locteron ® 58 polymerase inhibitor 58 CINQUIL 58 treprostinil 58 ANG# 58 Oracea TM 58 carcinogenicity study 58 abatacept Orencia 58 MKC# MKC# PP 58 mGluR5 negative 58 dose escalation 58 cilengitide 58 pramlintide metreleptin 58 post operative ileus 58 PF # [001] 58 romidepsin novel 58 metformin sulfonylurea 58 ANCHOR trial 58 double blinded placebo 58 ascending doses 58 tesofensine 58 AKT inhibitor 58 Preos 58 Hyphanox 58 Novolimus 58 pharmacological chaperone 58 mTOR inhibitor 58 rFVIIIFc 58 EDEMA3 trial 58 xanthine oxidase inhibitor 58 SGS# 58 Zelrix 58 Squalamine 58 volociximab 58 viral kinetic 58 Probuphine 58 Parkinson disease levodopa induced 58 Methylnaltrexone 58 cell lymphoma CTCL 58 APOPTONE 58 Rotigotine 58 placebo controlled Phase III 58 SAR# [002] 58 ADP receptor antagonist 58 pralatrexate 58 immunotherapeutic agent 58 IMiDs ® 58 opioid induced constipation 58 Elesclomol 58 Arikace 58 novel histone deacetylase 58 CD# CEA 58 Tarvacin TM 58 tasocitinib 58 investigational protease inhibitor 58 Perforomist ™ Inhalation Solution 58 Aryplase 58 Octreolin 58 INT# [002] 58 Tekamlo 58 crofelemer 57 QLT# 57 ramelteon 57 telaprevir VX 57 IMGN# 57 generation antisense inhibitor 57 neuroprotective properties 57 varespladib 57 elacytarabine 57 Phase IIb Clinical Trial 57 vemurafenib 57 gepirone ER 57 mixed dyslipidemia 57 favorable pharmacokinetic profile 57 ATL/TV# 57 L Annamycin 57 Oglemilast 57 placebo controlled studies 57 NDA resubmission 57 Diabetic Macular Edema DME 57 PRISTIQ 57 Solulin 57 Cardio Vascu Grow 57 SNRI 57 Maribavir 57 IMiDs 57 taranabant 57 viral kinetics 57 Initiate Phase 57 trastuzumab DM1 57 LibiGel Phase III 57 HCV SPRINT 57 nitric oxide donating prostaglandin 57 ropinirole Requip 57 Relivar 57 Phase #/#a 57 eliglustat tartrate 57 Prestara 57 phase Ib clinical 57 RhuDex ® 57 multicenter Phase III 57 registrational trials 57 Intravenous CP 57 valopicitabine 57 Anturol TM 57 HuMax CD4 57 ALN RSV# 57 bosentan 57 oral calcitonin 57 ADAGIO study 57 HFA MDI 57 SonoLysis 57 VEGF inhibitors 57 evaluating Actimmune 57 Denufosol 57 decitabine 57 SPC# [001] 57 novel oral anticoagulant 57 edifoligide 57 AIR CF1 57 ACTEMRA 57 macitentan 57 CIPN 57 Perforomist TM Inhalation Solution 57 carfilzomib 57 Xcytrin R 57 tesetaxel 57 ALB # 57 docetaxel Taxotere ® 57 EVIZON TM 57 dose escalation trial 57 LATUDA 57 Diamyd R 57 MNTX 57 Intermezzo R 57 Angiocept 57 Nanobody ® 57 NMDA antagonist 57 Phase IIIb study 57 initiate Phase IIb 57 Dacogen injection 57 heterozygous FH 57 oral FTY# 57 pharmacodynamic 57 interferon gamma 1b 57 Aliskiren 57 mg dose 57 IAP inhibitor 57 sargramostim 57 adenosine injection 57 lenalidomide Revlimid R 57 candidate CRLX# 57 placebo controlled 57 standard chemotherapy regimen 57 CCR5 antagonist 57 AZILECT ® 57 ASA# 57 postoperative ileus POI 57 ALN HTT 57 Zytiga